Dr. John Cush RheumNow
6 years 2 months ago
Based on a small number of studies (n = 5), there is little evidence to support the superiority (efficacy & safety) of Loading dose regimens when starting biologic (abatacept, certolizumab and secukinumab) therapy. https://t.co/0lNUzTFIOK
Dr. John Cush RheumNow
6 years 2 months ago
Sandoz rituximab biosimilar(SDZ-RTX; Rixathon) compared with reference rituximab (Ref-RTX) and shown to have same efficacy outcomes (DAS28 Remission, ACR20/50/70, CDAi/SDAI, HAQ), B cell depletion levels, adverse events & low level antidrug Abs https://t.co/0XWQs23Xcv
Dr. Jack Cush reviews the news and TOP 13 list of Best Rheumatology Hospitals.
Dr. John Cush RheumNow
6 years 2 months ago
Fracture risk & prevalence of osteoporosis is elevated in patients with idiopathic inflammatory myopathies: cross-sectional comparison of 52 myositis and 43 RA pts. OP Prevalence higher in the myositis group (13.5% v 7%) but equal fracture risk (68 v 75%) https://t.co/XT6O9HoqdH
Dr. John Cush RheumNow
6 years 2 months ago
Safety & efficacy of rituximab in Older RA (>65; n=97) vs younger (<65yrs; n=276) showed no difference in drug survival over 2 yrs (72% vs 74%)or SDAI activity. BUT.. there were more SIE (14.2 vs 6.6/100 PY) & pneumonia (10.7 vs 5.1/100 PY) in older pts https://t.co/dxqPg2fOlV
Dr. John Cush RheumNow
6 years 2 months ago
FDA recommends health care professionals discuss naloxone with all patients when prescribing opioid pain relievers or medicines to treat opioid use disorder. Naloxone can be administered(+/- medical training) to help reduce opioid overdose deaths https://t.co/9B0hPhOm57
A proof-of-concept study published in Annals of Rheumatic Disease suggests that colchicine significantly improves COVID-19 outcomes.
Efficacy and safety must be determined in controlled clinical trials.he outbreak of COVID-19 posed the issue of urgently identifying treatment strategies. Colchicine was considered for this purpose based on well-recognised anti-inflammatory effects and potential antiviral properties.
Congratulations on choosing the greatest profession, one equally dedicated to both science and patient care. You are now part of a guild that will support you and anticipate your success. Rheumatology needs you to be a big thinking, futuristic problem-solving practitioner who will lead and learn, research and teach. Here are my words of wisdom for aspiring MSK phenoms.
Dr. John Cush RheumNow
6 years 2 months ago
Metanalysis of 10 studies ( p534 patients) shows that exercise in ankylosing spondylitis improves pain, function and disease activity. Statistically signif improvement in pain (P<0.0001), BASDAI (P <0.00001), and BASFI (P<0.00001), but not CRP and ESR. https://t.co/fKo9kNOrmO
Dr. John Cush RheumNow
6 years 2 months ago
Lenabasum (cannabinoid rcptr agonist) studied in Systemic Sclerosis - LEN (n=27) vs PBO (n=15). At wk 16 LEN had better responses by CRISS (skin) score (0.33, vs 0; P=0.07) w/ reduced gene expression for inflammation & fibrosis & improved skin histology https://t.co/oddSMvjnc9 https://t.co/HLFPNfigFD
Vinay Prasad VPrasadMDMPH
6 years 2 months ago
The only thing worse than bad covid research is a meta-analysis of bad covid research
Eric Topol EricTopol
6 years 2 months ago
Important finding of marked lung fibrosis (scarring) after severe #COVID19 in 8 patients https://t.co/Akp6jVXmB9 @TheLancetInfDis
(first complete pathologic description of this finding) https://t.co/QCuri3olgs
Elizabeth Graef SituationRheum
6 years 2 months ago
I have a rheumatology joke but it’s painful https://t.co/TUj1nY4JD4
Peter Nash drpnash
6 years 2 months ago
Platelet Rich Plasma Versus Hyaluronic Acid in the Treatment of Knee Osteoarthritis: a Meta-Analysis of 26 randomized controlled trials #osteoarthritis #knee #PRP #HA metanalysis favours PRP! https://t.co/Z5Olucs3ku
